Hyperprolactinemia in systemic lupus erythematosus?
B Ostendorf, R Fischer, R Santen… - Scandinavian journal …, 1996 - Taylor & Francis
B Ostendorf, R Fischer, R Santen, B Schmitz-Linneweber, C Specker, M Schneider
Scandinavian journal of rheumatology, 1996•Taylor & FrancisThe objective of this project was to determine the prevalence of hyperprolactinemia (HPRL)
in systemic lupus erythematosus (SLE) and to evaluate the role of prolactin (PRL) as a
disease-activity marker. We determined PRL in a cohort of 182 patients with SLE. Basal
prolactin levels and clinical data (disease-activity index, sero-activity, medications) were
analyzed in all patients. The findings show only mildly elevated PRL levels in four SLE-
patients and normaprolactinemia in 98%(n= 178), without any association with disease …
in systemic lupus erythematosus (SLE) and to evaluate the role of prolactin (PRL) as a
disease-activity marker. We determined PRL in a cohort of 182 patients with SLE. Basal
prolactin levels and clinical data (disease-activity index, sero-activity, medications) were
analyzed in all patients. The findings show only mildly elevated PRL levels in four SLE-
patients and normaprolactinemia in 98%(n= 178), without any association with disease …
The objective of this project was to determine the prevalence of hyperprolactinemia (HPRL) in systemic lupus erythematosus (SLE) and to evaluate the role of prolactin (PRL) as a disease-activity marker. We determined PRL in a cohort of 182 patients with SLE. Basal prolactin levels and clinical data (disease-activity index, sero-activity, medications) were analyzed in all patients. The findings show only mildly elevated PRL levels in four SLE-patients and normaprolactinemia in 98% (n = 178), without any association with disease activity.
Our results differ from previous studies. HPRL appears not to be prevalent in SLE, nor to be associated with disease activity.
Taylor & Francis Online